# Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2.

> **NCT01339962** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 1073 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **OTHER:** Non-interventional

## Key facts

- **NCT ID:** NCT01339962
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 1073 (ACTUAL)
- **Last updated:** 2014-08-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01339962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01339962, "Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01339962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*